GALEAS™ Bladder
GALEAS Bladder is a biomarker test developed with Nonacus’s advanced technology, setting a new standard for the early detection and monitoring of bladder cancer.
This comprehensive test delivers cystoscopy-level accuracy for all grades and stages of bladder cancer using a simple urine sample.
With over 90% sensitivity, GALEAS Bladder offers a non-invasive, sample-to-report molecular triage for hematuria patients, helping urologists make informed decisions about further investigation.
GALEAS™ Tumor
A clinically validated panel designed in parallel with variant calling software for comprehensive genomic profiling of solid tumors.
GALEAS Tumor profiles key DNA biomarkers across 519 genes streamlining the detection of SNVs, INDELs, CNVs, TMB and MSI into a single workflow. Cloud-based bioinformatic pipelines enable rapid integration into any laboratory.
GALEAS™ HereditaryPlus
GALEAS HereditaryPlus offers an advanced solution for assessing hereditary cancer risk. It provides high sensitivity and reliability in genetic analysis as a comprehensive hereditary cancer test, designed to reduce the need for MLPA with specialized bioinformatics.
Covering 146 genes known to be associated with hereditary cancer, GALEAS HereditaryPlus is an expertly curated NGS panel that fully aligns with the UK National Genomic Test Directory and complies with ESMO/AMP guidelines.
Nonacus has an extensive publication portfolio that supports our innovative solutions in genetic and genomic analysis. We are proud to share our contributions and latest research findings with the scientific community. Our publications range from non-invasive prenatal testing (NIPT) to cancer genomic analysis and make significant contributions to scientific progress. Below, you can explore our latest research and studies.